2023 World Conference on Lung Cancer (Posters)-P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases

P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases - PDF(Slides)

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the efficacy and safety of furmonertinib 160mg as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations and central nervous system (CNS) metastases. The study included 20 patients who received furmonertinib 160mg orally once daily until disease progression or intolerable toxicity. The clinical efficacy was assessed based on CNS progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as overall PFS, ORR, and DCR. The median follow-up was 372.5 days, and the median PFS and CNS PFS were not yet reached. The CNS PFS rate at 6, 12, and 18 months was 94.4%, 81.2%, and 73%, respectively. The ORR assessed by the investigator was 90%, and the DCR was 100%. In the CNS evaluable for response set, the CNS ORR was 93.8%, and the CNS DCR was 100%. Tumor shrinkage was observed in all patients. The most common treatment-related adverse events were diarrhea and rash, with most being grade 1-2 and only one patient experiencing a grade 3 rash. Dose reduction and interruption were reported in a small percentage of patients, and no treatment discontinuation or deaths due to adverse events were reported. The study concluded that furmonertinib 160mg showed excellent efficacy and was well-tolerated as a first-line therapy for EGFR-mutated advanced NSCLC patients with CNS metastases.

Asset Subtitle

Xixi Zheng

Meta Tag

Speaker Xixi Zheng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

retrospective study

furmonertinib

first-line therapy

NSCLC

EGFR mutations

CNS metastases

efficacy

safety

tumor shrinkage

adverse events